Marked Clinical Improvement of Psoriasis Vulgaris with Methotrexate: A Case Report with 75% PASI Reduction
Abstract
Psoriasis is an immune-mediated chronic, recurrent, systemic inflammatory disease induced by the combination of hereditary and environmental factors. The etiology of this disease involves many factors, including genetics, immunology, and the environment. Clinically, psoriasis vulgaris is characterized by the presence of reddish plaques with thick, symmetrically distributed squama mainly in the predilection areas. In moderate to severe cases, systemic therapy such as phototherapy, systemic anti-inflammatory agents, or biologic treatments is required, with topical therapy serving as an adjunct. Methotrexate is one of the effective systemic treatment options for severe psoriasis, either as monotherapy or in combination regimens. This case report aims to demonstrate the clinical efficacy of methotrexate in the management of moderate-to-severe psoriasis vulgaris. We report a case of a 37-year-old male presenting with scaly reddish skin thickening accompanied by itching all over the body. Clinical and histopathological examination confirmed the diagnosis of Psoriasis Vulgaris and treated with methotrexate. After a period of regular weekly methotrexate administration and monitoring, the patient achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI), indicating significant therapeutic response. This case highlights the efficacy of methotrexate as a cost-effective and accessible treatment option for achieving substantial disease control in psoriasis vulgaris.
References
Boehncke, W. H., & Schön, M. P. (2015). Psoriasis. The Lancet, 386(9997), 983–994. https://doi.org/10.1016/S0140-6736(14)61909-7
Elmets, C. A., Leonardi, C. L., Davis, D. M. R., Gelfand, J. M., Armstrong, A. W., Connor, C., ... & Van Voorhees, A. S. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology, 80(4), 1073–1113. https://doi.org/10.1016/j.jaad.2018.11.058
Feldman, S. R., & Krueger, G. G. (2005). Psoriasis assessment tools in clinical trials. Annals of the Rheumatic Diseases, 64(Suppl 2), ii65–ii68. https://doi.org/10.1136/ard.2004.033902
Gudjonsson, J. E., & Elder, J. T. (2019). Psoriasis. In S. Kang, M. Amagai, A. L. Bruckner, A. H. Enk, D. J. Margolis, A. J. McMichael, & J. S. Orringer (Eds.), Fitzpatrick’s Dermatology (9th ed., pp. 457–497). McGraw-Hill Education.
Iskandar, I. Y. K., Parisi, R., Griffiths, C. E. M., & Ashcroft, D. M. (2021). Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. British Journal of Dermatology, 184(2), 243–258. https://doi.org/10.1111/bjd.19169
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., ... & Bhushan, R. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 80(4), 1029–1072. https://doi.org/10.1016/j.jaad.2018.11.057
Parisi, R., Iskandar, I. Y. K., Kontopantelis, E., Augustin, M., Griffiths, C. E. M., & Ashcroft, D. M. (2020). National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ, 369, m1590. https://doi.org/10.1136/bmj.m1590
Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, 20(6), 1475. https://doi.org/10.3390/ijms20061475
van Huizen, A. M., Menting, S. P., Gyulai, R., Rivera-Oyola, R., Lebwohl, M. G., & van de Kerkhof, P. C. M. (2022). International consensus on methotrexate dosing regimen in psoriasis: An eDelphi study. JAMA Dermatology, 158(5), 561–564. https://doi.org/10.1001/jamadermatol.2022.0264
Copyright (c) 2025 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
